Webinars - from Kline's Healthcare Practice

We focus on healthcare products sold through all channels of distribution,
including OTC pharmaceuticals, Rx-to-OTC switches, and more. Our studies are ideal for manufacturers, marketers, retailers and suppliers who are seeking a deeper understanding of their industry.

Our webinars are designed to provide key insights into market data on given topics, and to help customers familiarize themselves with our report contents.

Industry consolidation, major new brand launches, and a series of mergers and acquisitions in the U.S. OTC market have caused OTC cost structures to shift both in the near- and long-term. The costs associated with marketing, sales, and promotions of OTC brands tend to have wider swings from year to year, offset by administrative and R&D costs tend to be more stable over time.
During this live webinar, Laura Mahecha, Kline’s Healthcare Industry Manager, will reveal key findings from our just published OTC Drugs: U.S. Competitor Cost Structures report which provides the profitability of the 11 leading OTC companies’ OTC units and the top three OTC product classes of each company profiled.

The nonprescription drugs market in the U.S. continues to experience solid growth on almost all fronts, with the upper respiratory and digestive products increasing the fastest in terms of sales.
Recent switches, the return to market of major brands that had been previously recalled, and branded innovations continue to drive sales growth. Above average growth rates within some categories are propelled by new switch brands being launched and bringing prescription users to the OTC market.

Join Laura Mahecha, Kline’s Healthcare Industry Manager, for an insightful presentation on our soon-to-be-published Nonprescription Drugs USA report. Driven primarily by brands like, J&J and Novartis who made a comeback, new OAB OTC category created by Merck with the launch of Oxytrol for Women and increased ad spending, the U.S. OTC market has seen solid gains in 2013. Among the most important factors that influenced the market growth are strong gains for lower priced private-label OTCs as well as low levels of innovation.

In the nonprescription drugs market, it was private-label sales that grew astronomically. The convergence of price-conscious consumers and aggressive private-label marketing by mass retailers made these products thrive. What happened in 2010? Did natural OTCs (drug-free) become a new trend? What is the relative size of such products compared to traditional OTCs?

This webinar provides an overview of key insights on the financial performance, profitability, and costs structures of the ten leading OTC companies in the United States for 2008 and 2009. The report was designed to help OTC pharmaceutical companies benchmark their cost structures with those of their competitors.

The webinar provides highlights of objective, independent forecasts of future Rx-to-OTC switches and their expected impacts on the OTC market covered in the report. This analysis provides forecasts of future switches in existing OTC categories and projections for new OTC categories.